agilon health, inc. (AGL) Shareholder Investigation

Shamis & Gentile, P.A., a law firm focused on shareholder rights and corporate governance matters, is investigating potential claims on behalf of agilon health, inc. (“agilon” or the “Company”) (AGL) investors following recent financial disclosures and leadership changes. Concerned shareholders are advised to contact the firm now.

Shamis & Gentile is reviewing whether agilon’s board of directors and senior officers failed to maintain adequate oversight and internal controls over financial reporting and risk-adjustment forecasting, and whether these governance lapses contributed to the Company’s losses and reputational harm.

On November 2, 2023, agilon reported third-quarter results showing higher medical costs and lowered its full-year Medical Margin guidance from $500–$530 million to $455–$470 million. On January 5, 2024, the Company again cut forecasts by more than $110 million and announced the planned retirement of CFO Timothy Bensley. Following these disclosures, agilon’s stock fell 13.2% to $14.66 on November 3, 2023 and another 28.6% to $8.63 on January 5, 2024; significantly reducing shareholder value.

Thereafter, securities litigation was initiated against the Company. The complaint alleges defendants misled investors about agilon’s medical costs by: (1) touting the Company’s purported visibility into utilization trends and medical costs; (2) failing to disclose increased medical costs that agilon had incurred prior to and during the Class Period due to higher utilization of healthcare by MA patients; (3) falsely stating that its IBNR Reserve was adequate; (4) making false and misleading statements about the effectiveness of its business model; (5) issuing overly optimistic financial guidance; and (6) issuing risk disclosures that were materially false and misleading because they characterized adverse facts that had already materialized as mere possibilities.

On August 4, 2025, agilon reported second-quarter 2025 results that showed a net loss of $104 million and a negative medical margin. In connection with these results, management suspended all full-year 2025 guidance and announced the immediate departure of CEO Steve Sell. The Company also disclosed that its enhanced data platform indicated that 2024 and 2025 risk-adjustment revenue was lower than previously expected, resulting in reductions totaling $85 million ($37 million for 2024 and $48 million year-to-date 2025). On this news, agilon’s share price fell approximately 25% in pre-market trading, and declined from $1.81 per share at the August 4 close to $0.88 per share at market close on August 5; about 51% day over day, erasing hundreds of millions of dollars in market value.

A shareholder action seeks to recover damages on behalf of the Company and may result in corporate governance reforms designed to prevent similar issues in the future. If you have held agilon health, inc. (NYSE: AGL) shares since at least May 2023, you may be able to seek corporate reforms, the return of funds back to agilon, and a court-approved incentive award for you, all at absolutely no cost.

Shamis & Gentile, P.A. stands out as an advocate for shareholders seeking corporate accountability and governance reforms. The firm is committed to pursuing derivative actions that benefit companies and their shareholders by recovering damages and implementing meaningful corporate governance improvements. Shamis & Gentile has recovered over $1 billion for consumers nationwide. Its extensive experience, expertise and resources enable the firm to resolve disputes in a wide range of matters, including derivative actions, class actions and complex commercial litigation.

Attorney advertising. Prior results do not guarantee similar outcomes.